^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/21/2023
Excerpt:
Peripheral T-Cell Lymphomas: SUGGESTED TREATMENT REGIMENS ALCL…ALK inhibitors (for ALK-positive ALCL only)…lorlatinib…
